The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2021 | ADMIRAL: gilteritinib for R/R FLT3-mutated AML
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the two-year follow-up data from the ADMIRAL trial (NCT02421939). This trial investigated gilteritinib versus salvage chemotherapy as a treatment for patients with relapsed or refractory (R/R) FMS-like tyrosine kinase 3 (FLT3) mutated acute myeloid leukemia (AML). Despite a discouraging primary analysis, the two-year follow-up demonstrated promising data on long-term survival of patients treated with gilteritinib. Dr Levis comments on how the effect of transplants was considered when determining the benefit of gilteritinib and gives an overview of the two-year follow-up results. Two-year follow-up analysis concluded that gilteritinib was more effective than salvage chemotherapy for treating patients with R/R FLT3-mutated AML. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
